Traws Pharma (TRAW) EBIT Margin (2012 - 2025)
Traws Pharma (TRAW) posted quarterly EBIT Margin of 45.7% for Q2 2025, up 21635430.0% year-over-year from N/an in Q2 2024, and up 99.5% quarter-over-quarter from 9128.07% in Q1 2025.
Traws Pharma (TRAW) EBIT Margin (2012 - 2025) Analysis & Trends
Traws Pharma (TRAW) has reported EBIT Margin for 14 consecutive years, with 45.7% the latest figure, recorded in Q2 2025.
- In Q2 2025, EBIT Margin rose 21635430.0% year-over-year to 45.7%; the TTM figure through Dec 2025 stood at 640.68% (up 6235666.0% YoY), while the FY2025 annual figure was 640.68%, up 6235666.0% from the prior year.
- EBIT Margin improved to 45.7% in Q2 2025 per TRAW's latest filing, from 9128.07% in the prior quarter.
- Across five years, EBIT Margin topped out at 45.7% in Q2 2025 and bottomed at 216400.0% in Q2 2024.
- Historically, EBIT Margin has averaged 19952.94% across 5 years, with a median of 8538.6% in 2021.
- Annual changes were most pronounced in 2024 — EBIT Margin tumbled 20831228 bps — and 2025, when it jumped 21635430 bps.
- Traws Pharma's EBIT Margin stood at 6719.64% in 2021, then tumbled by 52 bps to 10239.29% in 2022, then gained by 22 bps to 7967.86% in 2023, then fell by 18 bps to 9425.0% in 2024, then jumped by 100 bps to 45.7% in 2025.
- Business Quant data shows TRAW's EBIT Margin at 45.7% in Q2 2025, 9128.07% in Q1 2025, and 9425.0% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Traws Pharma | 5.60 Mn | 588,417.40 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -45.70% |
| Mar 31, 2025 | -9,128.07% |
| Dec 31, 2024 | -9,425.00% |
| Sep 30, 2024 | -14,975.44% |
| Jun 30, 2024 | -216,400.00% |
| Mar 31, 2024 | -9,307.14% |
| Dec 31, 2023 | -7,967.86% |
| Sep 30, 2023 | -8,928.07% |
| Jun 30, 2023 | -8,087.72% |
| Mar 31, 2023 | -10,958.93% |
| Dec 31, 2022 | -10,239.29% |
| Sep 30, 2022 | -9,896.49% |
| Jun 30, 2022 | -7,228.07% |
| Mar 31, 2022 | -7,378.57% |
| Dec 31, 2021 | -6,719.64% |
| Sep 30, 2021 | -7,000.00% |
| Jun 30, 2021 | -8,149.12% |
| Mar 31, 2021 | -7,317.86% |
| Dec 31, 2020 | -10,973.68% |
| Sep 30, 2020 | -9,506.06% |